SCHEMBL1132501

SCHEMBL1132501

CSCC[C@@H](N)C(=O)NCCc1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 3/20 1.00
NLN Q9BYT8 1/20 0.63
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
TSHR P16473 2/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
PKM P14618 1/20 0.59
CYP2C19 P33261 1/20 0.59
BLM P54132 1/20 0.59
HDAC8 Q9BY41 1/20 0.58
ALDH1A1 P00352 2/20 0.58
MAPT P10636 2/20 0.58
KDM4E B2RXH2 1/20 0.58
CYP3A4 P08684 1/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
IDO1 P14902 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132068 1.00 CTSC (1.00) CTSCNLNMEN1KMT2ATSHR
SCHEMBL11768907 0.88 CTSC (0.79) CTSCNLNMEN1KMT2ATSHR
SCHEMBL1132343 0.86 CTSC (0.76) CTSCMEN1KMT2ALMNACYP1A2
SCHEMBL7620303 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL20465803 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL1132875 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL1132347 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL1132363 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL18381197 0.84 CTSC (0.72) CTSCNLNMEN1KMT2ATSHR
SCHEMBL15398876 0.83 CTSC (0.71) CTSCNLNMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025088286-A1 ECOBIOLOGICAL COMPOSITION CAPABLE OF PREVENTING AND TREATING REDNESS, SIGNS OF SKIN AGEING, AND VASCULAR ANOMALIES NAOS INSTITUTE OF LIFE SCIENCE (FR) 2025-05-01 WO claimed
WO-2025088285-A1 ECOBIOLOGICAL TOPICAL COMPOSITION FOR TREATING SKIN REDNESS AND DISCOMFORT NAOS INSTITUTE OF LIFE SCIENCE (FR) 2025-05-01 WO claimed
EP-1408032-B1 Coupling product between tryptamine and an alpha-amino acid and its use in the field of neuro-cosmetics EXSYMOL SA (MC) 2011-02-16 EP claimed
US-7094796-B2 Coupling product between tryptamine and an alpha-amino acid, process for its preparation as well as its application in the neurocosmetic field EXSYMOL S.A.M. (MC) 2006-08-22 US claimed
US-20040110814-A1 Coupling product between tryptamine and an alpha-amino acid, process for its preparation as well as its application in the neurocosmetic field EXSYLMOL S.A.M. 2004-06-10 US claimed
EP-1408032-A2 Coupling product between tryptamine and an alpha-amino acid and its use in the field of neuro-cosmetics EXSYMOL S.A.M. (MC) 2004-04-14 EP claimed
WO-2025088286-A1 ECOBIOLOGICAL COMPOSITION CAPABLE OF PREVENTING AND TREATING REDNESS, SIGNS OF SKIN AGEING, AND VASCULAR ANOMALIES NAOS INSTITUTE OF LIFE SCIENCE (FR) 2025-05-01 WO disclosed
WO-2025088285-A1 ECOBIOLOGICAL TOPICAL COMPOSITION FOR TREATING SKIN REDNESS AND DISCOMFORT NAOS INSTITUTE OF LIFE SCIENCE (FR) 2025-05-01 WO disclosed
EP-1408032-B1 Coupling product between tryptamine and an alpha-amino acid and its use in the field of neuro-cosmetics EXSYMOL SA (MC) 2011-02-16 EP disclosed
US-7094796-B2 Coupling product between tryptamine and an alpha-amino acid, process for its preparation as well as its application in the neurocosmetic field EXSYMOL S.A.M. (MC) 2006-08-22 US disclosed
US-20040110814-A1 Coupling product between tryptamine and an alpha-amino acid, process for its preparation as well as its application in the neurocosmetic field EXSYLMOL S.A.M. 2004-06-10 US disclosed
EP-1408032-A2 Coupling product between tryptamine and an alpha-amino acid and its use in the field of neuro-cosmetics EXSYMOL S.A.M. (MC) 2004-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110814-A1 Coupling product between tryptamine and an alpha-amino acid, process for its preparation as well as its application in the neurocosmetic field TPH1, IDO1, KYNU CTSC 1123/4885NLN 82/4885MEN1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.